Migrenofen (Rizatriptan Benzoate)

Rizatriptan benzoate, the active ingredient in Migrenofen, is a selective serotonin 5‑HT1B/1D receptor agonist presented as an oral tablet for systemic use. It is indicated for the acute treatment of migraine attacks in adults. It works by constricting cranial blood vessels and blocking pain pathways, offering rapid relief for patients experiencing moderate to severe migraine symptoms.

GNH USA supplies Migrenofen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Migrenofen (rizatriptan) is a triptan that targets serotonin 5‑HT1B/1D receptors to treat migraine. - Migraine without aura: provides rapid relief of headache pain, reduces nausea and improves functional ability during an attack. - Migraine with aura: aborts attacks after onset of visual or sensory aura, diminishing headache intensity and associated symptoms. - Acute episodic migraine: shortens the duration of migraine episodes and alleviates photophobia, phonophobia and vomiting.

Rizatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Chest tightness - Tingling or numbness in extremities - Dizziness

Serious or Rare Side Effects: - Serotonin syndrome - Coronary vasospasm - Severe allergic reaction (anaphylaxis)

When prescribing Migrenofen, clinicians should consider several safety measures. - Assess cardiovascular risk: evaluate history of heart disease before prescribing. - Avoid in uncontrolled hypertension: high blood pressure may increase vasoconstrictive effects. - Do not combine with other triptans: additive vasoconstriction can occur. - Review serotonergic medication use: concurrent SSRIs, SNRIs, or MAO inhibitors raise serotonin syndrome risk. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Rizatriptan interacts with several drug classes that may require avoidance or close monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin toxicity. - SSRIs, SNRIs, or other serotonergic agents: may precipitate serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstriction can lead to cardiovascular events.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: rizatriptan may enhance blood pressure‑lowering effects. - CYP3A4 inhibitors: may increase plasma concentrations of rizatriptan.